HK Stock Market Move | LEADS BIOLABS-B(09887) up more than 8% again, TCE dual antibody LBL-034 receives FDA fast track designation.

LEADS BIOLABS-B(09887) rose more than 8%, as of press time, it increased by 7.29%, to 64.75 Hong Kong dollars, with a turnover of 4491.77 million Hong Kong dollars. On the news front, Vital Therapies announced that on January 27, the company's independently developed GPRC5D/CD3 bispecific antibody LBL-034, with a unique 2:1 structure and conditionally activated based on the TCE technology platform LeadsBody, has been granted fast track designation by the US Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma. Huafu Securities released a research report stating that Vital Therapies is strategically positioning itself in the next generation of cancer immunotherapy through its agonist platform+TCE platform+ADC. From the X-body platform in 2015, the LeadsBody platform in 2016, to the subsequent accumulation of bispecific and trispecific technologies, the company has always focused on "technology platform+innovative targets", covering cutting-edge fields such as immune checkpoints and multispecific antibodies, and building a differentiated pipeline.